Environmental

AXGN’s R&D intensity is materially above many medtech peers, supporting product innovation but also increasing resource use and development-related environmental footprint.

The company’s asset-light capital structure likely limits direct manufacturing emissions versus vertically integrated peers, although the provided data do not show formal emissions disclosure.

No evidence in the supplied metrics indicates superior environmental management systems, so its relative position appears closer to average than best-in-class peers.

Social

AXGN’s high R&D-to-revenue ratio suggests sustained investment in medically relevant innovation, which is a positive social factor versus slower-investing peers.

The company’s gross margin profile implies pricing power from specialized products, which can support continued access to clinically differentiated offerings relative to peers.

Stock-based compensation remains elevated, but the metric alone does not indicate a peer-level social weakness unless it translates into retention or culture issues.

Governance

AXGN’s low debt-to-equity ratio indicates conservative balance-sheet governance relative to more leveraged peers, reducing financial stress and oversight risk.

However, net debt to EBITDA is still elevated, which can constrain governance flexibility versus stronger peers with cleaner leverage profiles.

Stock-based compensation at a meaningful level suggests dilution oversight remains relevant, although the provided data do not indicate a severe governance controversy.

Overall Score

AXGN’s ESG profile is mixed but slightly above average versus peers, led by stronger social positioning and disciplined leverage, offset by limited disclosed environmental leadership.

Score Driver: Sustained R&D Investment Supporting Socially Relevant Innovation